Evolving First-Line Treatment Strategies for uHCC.

James J. Harding, MD, provides a high-level overview of systemic therapy for untreated unresectable hepatocellular carcinoma (uHCC) based on NCCN Guidelines, and discusses the evolving treatment landscape, including the rationale for combination immunotherapy (IO) and how additional IO combinations may address unmet needs like depth of response and resistance.

Now Viewing

EP: 1.Evolving First-Line Treatment Strategies for uHCC.

EP: 2.An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.

EP: 3.Academic Perspectives on Front-line Nivolumab/ Ipilimumab Therapy for uHCC.

EP: 4.Navigating Between Front-line Systemic Therapies in uHCC.

EP: 5.Patient Considerations for Front-line Systemic Immunotherapies in uHCC.

EP: 6.Future Outlook in Front-line Treatment for uHCC.

Video content above is prompted by the following:

Give a high-level overview of systemic therapy for untreated uHCC

Briefly dDiscuss the evolving treatment landscape of systemic therapy in untreated uHCC.

• What has been the rationale for combination immunotherapy (IO) in this setting?
• What are current unmet needs, and how could additional IO combinations address them?
• E.g,. depth of response, resistance,…

Recent Videos